Summa Equity invested in fish health specialist STIM partnering with its founder Jim-Roger Nordly.
“Aquaculture is one of the key building blocks in the sustainable food system of the future due to its low carbon footprint, scalability, and high feed efficiency. But as a young industry, it faces challenges related to fish welfare and mortality. Solving these challenges through disease prevention, sound production protocols, genetics, and nutrition will be key to unlocking the industry's full potential. STIM is ideally positioned to take the lead role in that transformation,” said Martin Gjølme, partner at Summa.
For over three decades STIM has contributed to a more sustainable aquaculture industry by providing innovations that improve fish health, growth, and profitability. The company is well-positioned in several markets through its knowledgeable teams and unique cross-disciplinary competence. The gross revenue of the company was north of EUR 150 million in 2023.
The partnership with Summa is motivated by STIM and founder Jim-Roger Nordly’s drive to establish new growth verticals, intensify product development, and expand its service offering in aquaculture worldwide.
“I am convinced that Summa is the right strategic and long-term partner for us. They recognize that our employees' expertise and efforts are the bedrock of this company. With Summa on our side, I am confident that STIM can become the world leader in sustainability and health, not just within the salmon industry, but for the seafood industry as a whole. There is a huge demand for advisory services within this sector, and that is something we have our eyes on,” said Jim-Roger Nordly, chairman and founder of STIM.
“We have followed STIM’s journey since the inception of Summa. STIM's expertise within fish health and biology is unparalleled, and with Summa’s long-term perspective and track record in the aquaculture industry, we are certain we can be a true partner in solving some of the largest challenges the industry is facing,” said Gjølme.
“Summa will be an important partner as we expand our strategic initiatives across existing and new markets. That being said, my focus is always to maintain business as usual at STIM. Our priority is to deliver products, services, solutions, and advice that contribute to positive biological outcomes and growth for our customers,” said Carl-Erik Arnesen, CEO of STIM.
